A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Conditions:   ALK-positive Non-small Cell Lung Cancer (NSCLC);   RET-positive Non-small Cell Lung Cancer (NSCLC);   RET-positive Thyroid Cancer
Intervention:   Drug: Alectinib
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
Not yet recruiting - verified April 2017

http://ift.tt/2oQA0Iv